A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
A Randomized, Open-Label, Controlled Phase 3 Study of Comparing Daratumumab, Lenalidomide and Dexamethasone Induction Followed by Linvoseltamab Versus Continued Daratumumab, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients
Sponsor: European Myeloma Network B.V.
This PHASE3 trial investigates Multiple Myeloma and is currently actively recruiting participants. European Myeloma Network B.V. leads this study, which shows 4 recorded versions since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
4 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE3
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Nov 2025 — Jan 2026 [monthly]
Not Yet Recruiting PHASE3
-
May 2025 — Nov 2025 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- European Myeloma Network B.V.
- Regeneron Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aarhus, Denmark , Ancona, Italy , Barcelona, Spain , Basel, Switzerland , Coimbra, Portugal , Florence, Italy , Genova, Italy , Heidelberg, Australia , Hradec Králové, Czechia , Izmir, Turkey (Türkiye) and 23 more locations